Fate Therapeutics Q1 2024 GAAP EPS $(0.47), Inline, Sales $1.925M Beat $1.114M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fate Therapeutics (NASDAQ:FATE) reported Q1 2024 GAAP EPS of $(0.47), matching analyst estimates, but with a 147.37% decrease from the previous year. Sales reached $1.925M, surpassing the $1.114M estimate but showing a 96.74% decrease from the previous year's $58.980M.
May 09, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fate Therapeutics reported a Q1 2024 EPS of $(0.47), in line with estimates, and sales of $1.925M, beating estimates but significantly lower than last year.
While Fate Therapeutics met EPS estimates and exceeded sales forecasts for Q1 2024, the significant year-over-year decrease in sales could concern investors. The EPS meeting expectations indicates stability, but the drastic sales drop might offset potential positive sentiment. The neutral score reflects the balance between meeting EPS estimates and the concerning decrease in sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100